Mammologix
  • Home
  • About
  • How It Works
    • Processing
    • What Clients Send
    • Letters
    • Overdue System
    • Reports
    • Special Reports
    • LogixDrive
    • Fiscal Matters
    • Getting Started
  • LogixLinks
    • LogixDrive
    • ACR
    • Breast Cancer Awareness
    • Dense Breast-Info
    • FDA MQSA
    • SBI
    • NQMBC
  • Moments
  • Help Center
  • Contact
  • Link Page

Sample Information In Executive MMOA Summary

Download Sample
A word about using the information contained with this Mammography Medical Audit
  1. Asymptomatic Mammograms
    1. Total studies initially assessed Needs Additional Imaging   Suspicious, or Highly Suggestive of Malignancy
    2. Total studies with final assessments of Suspicious
    3. Total studies with final assessments of Suspicious/Highly Suggestive of Malignancy that underwent biopsy
    4. Total studies with final assessments of Negative, Benign, and Probably Benign
    5. TN – True Negatives
      • TN1
      • TN2
    6. No Outcomes Reported To date on Final Event in Series
      • # of final assessments of Suspicious/Highly Suggestive of Malignancy that underwent biopsy with no outcome reported to date
      • # of Negative assessments with confirmed biopsy with no outcome reported to date
    7. % Recall – Asymptomatic Mammograms (Initial Visit))
    8. Total Initial Mammograms
    9. TP – Number of True Positives (MQSA Defined)
    10. FP – Number of False Positives – Based Upon a Subsequent Reported Benign Finding
      • FP1
      • FP2
      • FP3
    11. FN – Number of False Negatives
    12. PPV – Positive Predicted Value
      • PPV1
      • PPV2
      • PPV3
    13. Cancer Detection Rate (TP x 1000)/Total Initial Asymptomatic Mammograms
    14. Sensitivity
    15. Specificity
      • Specificity1
      • Specificity2
  2. Asymptomatic Initial Assessment Breakdown
    1. Assessment
    2. Count
    3. Percent
  3. Asymptomatic Final Assessment Breakdown
    1. Assessment
    2. Count
    3. Percent
    4. ASYMPTOMATIC PATIENTS WITH NO FINAL ASSESSMENT
  4. Asymptomatic Biopsy Breakdown
    1. Biopsy Type
    2. Count
    3. Percent
    4. BIOPSY PATIENT LISTING (by biopsy type)
  5. Symptomatic Mammograms (same information as #1.2)
  6. Symptomatic Assessment Breakdown (same information as #1.3)
  7. Symptomatic Final Assessment Breakdown (same information as #1.4)
  8. Symptomatic biopsy Breakdown (same information as #1.5)
  9. Aggregate Mammograms (same information as #1.2)
  10. Aggregate Initial Assessment Breakdown(same information as #1.3)
  11. Aggregate Final Assessment Breakdown (same information as #1.4)
  12. Aggregate Biopsy Breakdown (same information as #1.5)
  13. Patient Listings (asymptomatic mammograms)
  14. Patient Listings (symptomatic mammograms)
Mammologix Services, powered by I/O Trak, Inc.

Corporate Office
830 Sunshine Lane
Altamonte Springs, FL 32714-3902

Telephone
Toll Free: (800) 739-6919
Local:        (407) 790-7554
Email:       
mammologix@iotrak.helpscoutapp.com
Picture
© Copyright 2021. All Rights Reserved.
  • Home
  • About
  • How It Works
    • Processing
    • What Clients Send
    • Letters
    • Overdue System
    • Reports
    • Special Reports
    • LogixDrive
    • Fiscal Matters
    • Getting Started
  • LogixLinks
    • LogixDrive
    • ACR
    • Breast Cancer Awareness
    • Dense Breast-Info
    • FDA MQSA
    • SBI
    • NQMBC
  • Moments
  • Help Center
  • Contact
  • Link Page